NCT00642499View on ClinicalTrials.gov

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Highly Active Antiretroviral Therapy (HAART)-Related Nausea and VomitingHIV Infections
Interventions
DRUG

Dronabinol

2.5 mg to 40 mg

DRUG

Placebo

placebo

Trial Locations (36)

Unknown

Site 911, Bakersfield

Site 919, Fresno

Site 924, Los Angeles

Site 932, Los Angeles

Site 926, Palm Springs

Site 946, Pasadena

Site 913, Tarzana

Site 907, Altamonte Springs

Site 948, Miami

Site 951, Miami

Site 953, Miami

Site 959, Miami

Site 954, North Palm Beach

Site 957, Pensacola

Site 923, Port Saint Lucie

Site 929, Sarasota

Site 952, Tallahassee

Site 931, Tampa

Site 908, Decatur

Site 905, Boise

Site 914, Chicago

Site 928, Louisville

Site 955, Louisville

Site 958, New Orleans

Site 934, Boston

Site 915, Springfield

Site 956, Somers Point

Site 921, Albany

Site 910, Cincinnati

Site 941, Philadelphia

Site 925, Dallas

Site 917, Fort Worth

Site 906, Houston

Site 942, Houston

Site 909, Tacoma

Site 927, Vancouver

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00642499 - Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting | Biotech Hunter | Biotech Hunter